In January 2010, the FDA accepted the new drug application (NDA) for EZG for adjunctive treatment of epilepsy in adults with partial-onset seizures. US market entry is anticipated by 2011. EZG is the first potassium channel opener to reach late stage clinical development for the treatment of epilepsy. EZG's anticonvulsant properties are primarily mediated by opening or activating neuronal voltage-gated potassium channels. The efficacy and safety of EZG as part of polytherapy AED regimens in adults with refractory partial-onset seizures has been demonstrated in one Phase II and two Phase III double-blind, placebo-controlled trials: RESTORE 1 and 2.